IP Library Granted Patent US 7,368,122
Granted Patent B1
US 7,368,122 · App. 10/094,534 · Granted May 6, 2008

Skin cream

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,368,122
App. No.
10/094,534
Granted
May 6, 2008
Kind
B1
Abstract

An emulsion for topical application to the skin containing a high molecular weight emulsifier and substantially no emulsifiers of a molecular weight less than 100 kD. The emulsion may be used to prevent or treat dermatoses and may additionally contain pharmaceutically active ingredients.

Claims (50)

1. An emulsion for topical application to the skin comprising one or more acrylates/C10-C30 alkyl acrylate crosspolymer primary emulsifiers having a molecular weight of at least 100 kD, one or both of cetyl alcohol and stearyl alcohol, optionally a silicone oil at a concentration up to 0.5%, optionally cholesterol at a concentration up to 10%, and optionally stearic acid, wherein the emulsion contains an aqueous phase and an oil phase, wherein the oil phase constitutes 30% or less of the total formula weight of the emulsion and is free of materials other than silicones and triglycerides that are liquid at room temperature, and wherein the emulsion lacks any additional primary emulsifier having a molecular weight of less than 100 kD and is free of surface active film formers.

2. The emulsion of claim 1 wherein the oil phase constitutes 20% or less of the total formula weight of the emulsion.

3. The emulsion of claim 2 wherein the oil phase constitutes 15% or less of the total formula weight of the emulsion.

4. The emulsion of claim 1 which further comprises one or more of cholesterol at a concentration higher than 0.0%, a triglyceride containing one or more essential fatty acids, glycerin, and sorbitol.

5. The emulsion of claim 1 which comprises either or both of glycerin and sorbitol.

6. The emulsion of claim 1 which comprises cholesterol at a concentration higher than 0.0%.

7. The emulsion of claim 1 which comprises a triglyceride containing one or more essential fatty acids.

8. The emulsion of claim 1 which comprises cholesterol at a concentration higher than 0.0%, a triglyceride containing one or more essential fatty acids, and sorbitol.

9. The emulsion of claim 1 which is free of propylene glycol.

10. The emulsion of claim 1 which further comprises silicone oil at a concentration higher than 0.0%.

11. The emulsion of claim 1 which further comprises a pharmaceutically active ingredient.

12. The emulsion of claim 11 wherein the pharmaceutically active ingredient is a corticosteroid.

13. The emulsion of claim 11 wherein the pharmaceutically active ingredient is selected from the group consisting of isopropyl myristate, retinoic acid, benzoyl peroxide, a sunscreen, clindamycin, urea, metronidazole, miconazole, calcipotriol, hydrocortisone, and betamethasone.

14. The emulsion of claim 11 wherein the pharmaceutically active ingredient is metronidazole.

15. An emulsion for topical application to the skin comprising one or more acrylates/C10-C30 alkyl acrylate crosspolymer primary emulsifiers having a molecular weight of at least 100 kD, one or both of cetyl alcohol and stearyl alcohol, optionally a silicone oil at a concentration up to 0.5%, optionally cholesterol at a concentration up to 10%, and optionally stearic acid, wherein the emulsion contains an aqueous phase and an oil phase wherein the oil phase constitutes 30% or less of the total formula weight of the emulsion, wherein the emulsion lacks any additional primary emulsifier having a molecular weight of less than 100 kD and is free of surface active film formers, and wherein the emulsion does not break instantaneously upon contact with skin.

16. The emulsion of claim 15 wherein the emulsion does not break within the first 10 seconds of contact with skin.

17. The emulsion of claim 16 wherein the emulsion, when rubbed into the skin during the 10 seconds, does not break.

18. The emulsion of claim 15 wherein the emulsion does not break upon contact with the skin for one minute.

19. The emulsion of claim 15 wherein the oil phase of the emulsion is free of materials other than silicones and triglycerides that are liquid at room temperature.

20. The emulsion of claim 15 which is free of propylene glycol.

21. The emulsion of claim 15 which further comprises silicone oil at a concentration higher than 0.0%.

22. The emulsion of claim 15 which further comprises a pharmaceutically active ingredient.

23. The emulsion of claim 22 wherein the pharmaceutically active ingredient is a corticosteroid.

24. The emulsion of claim 22 wherein the pharmaceutically active ingredient is selected from the group consisting of isopropyl myristate, retinoic acid, benzoyl peroxide, a sunscreen, clindamycin, urea, metronidazole, miconazole, calcipotriol, hydrocortisone, and betamethasone.

25. The emulsion of claim 22 wherein the pharmaceutically active ingredient is metronidazole.

26. A method for treating skin or a mucous membrane comprising topically applying to the skin or to the mucous membrane an emulsion comprising one or more acrylates/C10-C30 alkyl acrylate crosspolymer primary emulsifiers having a molecular weight of at least 100 kD, one or both of cetyl alcohol and stearyl alcohol, optionally a silicone oil at a concentration up to 0.5%, optionally cholesterol at a concentration up to 10%, and optionally stearic acid, wherein the emulsion contains an aqueous phase and an oil phase, wherein the oil phase constitutes 30% or less of the total formula weight of the emulsion and is free of materials other than silicones and triglycerides that are liquid at room temperature, and wherein the emulsion lacks any additional primary emulsifier having a molecular weight of less than 100 kD and is free of surface active film formers.

27. The method of claim 26 wherein the emulsion does not break instantaneously upon contact with skin.

28. The method of claim 26 wherein the emulsion further comprises silicone oil at a concentration higher than 0.0%.

29. The emulsion of claim 26 wherein the emulsion further comprises a pharmaceutically active ingredient.

30. A method for treating skin or a mucous membrane comprising topically applying to the skin or to the mucous membrane an emulsion comprising one or more acrylates/C10-C30 alkyl acrylate crosspolymer primary emulsifiers having a molecular weight of at least 100 kD, one or both of cetyl alcohol and stearyl alcohol, optionally a silicone oil at a concentration up to 0.5%, optionally cholesterol at a concentration up to 10%, and optionally stearic acid, wherein the emulsion contains an aqueous phase and an oil phase wherein the oil phase constitutes 30% or less of the total formula weight of the emulsion, wherein the emulsion lacks any additional primary emulsifier having a molecular weight of less than 100 kD and is free of surface active film formers, and wherein the emulsion does not break instantaneously upon contact with skin.

31. The method of claim 30 wherein the emulsion does not break within the first 10 seconds of contact with skin.

32. The method of claim 31 wherein the emulsion, when rubbed into the skin during the 10 seconds, does not break.

33. The method of claim 30 wherein the emulsion does not break upon contact with the skin for one minute.

34. The method of claim 30 wherein the emulsion further comprises silicone oil at a concentration higher than 0.0%.

35. The method of claim 30 wherein the emulsion further comprises a pharmaceutically active ingredient.

36. The method of claim 30 wherein the emulsion is free of materials other than silicones and triglycerides that are liquid at room temperature.

37. The emulsion of claim 1 wherein the oil phase constitutes 30% or less of the total formula weight of the emulsion.

38. The emulsion of claim 15 wherein the oil phase constitutes 30% or less of the total formula weight of the emulsion.

39. The method of claim 26 wherein the oil phase constitutes 30% or less of the total formula weight of the emulsion.

40. The method of claim 30 wherein the oil phase constitutes 30% or less of the total formula weight of the emulsion.

41. The method of claim 26 wherein the skin or mucous membrane is irritated or afflicted with a disorder.

42. The method of claim 41 wherein the disorder is selected from the group consisting of hand dermatitis, eczema, atopic dermatitis, psoriasis, acne, rosacea, pruritus, and xerosis.

43. The method of claim 30 wherein the skin or mucous membrane is irritated or afflicted with a disorder.

44. The method of claim 43 wherein the disorder is selected from the group consisting of hand dermatitis, eczema, atopic dermatitis, psoriasis, acne, rosacea, pruritus, and xerosis.

45. The emulsion of claim 1 wherein the concentration of the acrylates/C10-C30 alkyl acrylate crosspolymer emulsifier is less than 0.5%.

46. The emulsion of claim 15 wherein the concentration of the acrylates/C10-C30 alkyl acrylate crosspolymer emulsifier is less than 0.5%.

47. A method for treating dermatitis comprising topically applying to skin afflicted with dermatitis an emulsion comprising one or more acrylates/C10-C30 alkyl acrylate crosspolymer primary emulsifiers having a molecular weight of at least 100 kD, one or both of cetyl alcohol and stearyl alcohol, optionally a silicone oil at a concentration up to 0.5%, optionally cholesterol at a concentration up to 10%, and optionally stearic acid, the oil phase constitutes 30% or less of the total formula weight of the emulsion and is free of materials other than silicones and triglycerides that are liquid at room temperature, and wherein the emulsion lacks any additional primary emulsifier having a molecular weight of less than 100 kD and is free of surface active film formers.

48. The method of claim 47 wherein the dermatitis is hand dermatitis.

49. A method for treating dermatitis comprising topically applying to skin afflicted with dermatitis an emulsion comprising one or more acrylates/C10-C30 alkyl acrylate crosspolymer primary emulsifiers having a molecular weight of at least 100 kD, one or both of cetyl alcohol and stearyl alcohol, optionally a silicone oil at a concentration up to 0.5%, optionally cholesterol at a concentration up to 10%, and optionally stearic acid, wherein the emulsion contains an aqueous phase and an oil phase wherein the oil phase constitutes 30% or less of the total formula weight of the emulsion, wherein the emulsion lacks any additional primary emulsifier having a molecular weight of less than 100 kD and is free of surface active film formers, and wherein the emulsion does not break instantaneously upon contact with skin.

50. The method of claim 49 wherein the dermatitis is hand dermatitis.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2019
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 049999/0001 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Jul 18, 2011
From: VALEANT PHARMACEUTICALS INTERNATIONAL, A DELAWARE CORPORATION; ATON PHARMA, INC., A DELAWARE CORPORATION; CORIA LABORATORIES, LTD., A DELAWARE CORPORATION; DOW PHARMACEUTICAL SCIENCES, INC., A DELAWARE CORPORATION; VALEANT PHARMACEUTICALS NORTH AMERICA LLC, A DELAWARE LLC; PRESTWICK PHARMACEUTICALS, INC., A DELAWARE CORPORATION; VALEANT BIOMEDICALS, INC., A DELAWARE CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 026606/0061 →
PATENT SECURITY RELEASE AGREEMENT Recorded Mar 14, 2011
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS NORTH AMERICA; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.; ATON PHARMA, INC.
Reel/Frame 025950/0048 →
SECURITY AGREEMENT Recorded Oct 4, 2010
From: ATON PHARMA, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA; VALEANT PHARMACEUTICALS INTERNATIONAL; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 025084/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2003
From: ALLERDERM LABORATORIES, INC.
To: DOW PHARMACEUTICAL SCIENCES
Reel/Frame 014256/0854 →